October 23, 2025
CAGE Bio Announces Start of Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo
San Carlos, CA; Fort Worth, TX
Event Details
October 23, 2025
CAGE Bio Announces Start of Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo
San Carlos, CA; Fort Worth, TX
September 4, 2025
CAGE Bio reports strong results from its phase 2B atopic dermatitis study
San Carlos, CA; Fort Worth, TX
Event Details
September 4, 2025
CAGE Bio reports strong results from its phase 2B atopic dermatitis study
San Carlos, CA; Fort Worth, TX
August 27, 2025
CAGE Bio Announces Collaboration to Advance First-in-Class Treatments for Graft vS. HosT DISEASE
San Carlos, CA; Fort Worth, TX
Event Details
August 27, 2025
CAGE Bio Announces Collaboration to Advance First-in-Class Treatments for Graft vS. HosT DISEASE
San Carlos, CA; Fort Worth, TX
January 9, 2025
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor
San Carlos, CA; Fort Worth, TX
Event Details
January 9, 2025
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor
San Carlos, CA; Fort Worth, TX
August 03, 2023
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic
San Carlos, CA; Fort Worth, TX
Event Details
August 03, 2023
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic
San Carlos, CA; Fort Worth, TX
More Events
Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
Welcome! Check out our latest news.
CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment